TELO
Telomir Pharmaceuticals, Inc.
Next earnings Aug 12, 2026 · consensus $-0.07 EPS
$1.24
▲ +0.81%$1.24▼ -18.95%
over 1Y
L $1.08EODHDH $2.29
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.8%
1W+0.8%
1M-3.9%
3M-0.8%
YTD-7.5%
1Y-19.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Conservative balance sheet (liabilities/equity 0.24x).
Return on equity -176.1% · latest
Telomir Pharmaceuticals, Inc. shows limited reported revenue, and -176.1% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | -$854K | -$13.1M | -$16.5M | -$10.4M |
| Diluted EPS | -$0.03 | $0.48 | -$0.56 | -$0.33 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$42.6M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-24.4%
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+15.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-152026-06-15open ↗3Period ending 2026-06-032026-06-09open ↗8-KPeriod ending 2026-06-032026-06-08open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗4Period ending 2026-05-212026-05-22open ↗8-KPeriod ending 2026-05-202026-05-20open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-04-242026-04-30open ↗4Period ending 2026-04-222026-04-24open ↗8-KPeriod ending 2026-04-222026-04-24open ↗
Frequently asked
- Is Telomir Pharmaceuticals, Inc. (TELO) a buy?
- TELO currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.24x).
- What is Telomir Pharmaceuticals, Inc.'s quality score?
- TELO scores 59.87179487179487/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001971532, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 8:33:12 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.